Please ensure Javascript is enabled for purposes of website accessibility

Time for a Turnaround at Teva Pharmaceuticals Industries Ltd?

By Seth Robey - Feb 3, 2014 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are Teva's management and patent woes finally a thing of the past?

Drugmaker Teva Pharmaceuticals (TEVA -0.18%) has had a few rocky years in an industry that has soared over the same period. The $38 billion generic pharmaceutical copmany has faced some serious management debacles and a looming patent expiration.

TEVA Chart

Teva Pharmaceuticals data by YCharts.

2014 has brought a glimmer of hope to the embattled company, but can new management and an improved blockbuster fend off competition from Biogen Idec (BIIB 0.53%) and Mylan (MYL)?

He did what??
When former CEO Jeremy Levin signed on to head Teva in 2012, he knew the job would entail some tough love to prepare for the impending patent expiration for blockbuster multiple sclerosis drug Copaxone. I'm sure he never guessed polygraph tests would be involved, though. After leaks revealed a rift in management's relationship with the Board of Directors over implementing cost cuts, Levin allegedly subjected board members to polygraph tests to plug the leak. That's not particularly Foolish management, and not surprisingly Levin departed the company soon after.

Now Teva has a new head in CEO Erez Vigodman. Vigodman has a history of reforming unprofitable businesses and plans to continue Levin's cost cutting initiatives. The execution of this plan in the coming years is critical to boosting the company's profitability.

A Copaxone reprieve?
While Teva is known as one of the largest generic drug manufacturers, 20% of its third quarter revenue came from the branded drug Copaxone. That revenue comes with a much higher margin than Teva's generic offerings, and contributes much more to net income. That means that when Copaxone loses patent protection in May of this year, Teva could face a big hit to its top line, and an even bigger hit to its bottom line. So far, management has been unable to protect that revenue with a failed Supreme Court injunction and poor results for new MS drug Nerventra.

Last week, Teva and its shareholders received some uplifting news when the FDA approved a new, longer acting three-per-week dose of Copaxone, granting that formulation market exclusivity. Copaxone could still face generic competition for its once-daily injection, and Mylan is hot on the chase with a biosimilar version slated to hit shelves as soon as the patent expires. The biosimilar still requires FDA approval, but it could spell trouble for Teva if approved. This leaves the company only a few months to convert patients to the new formulation before a major pricing war kicks in.

That conversation is moot, though, if Biogen keeps rolling as it has been. Sales of the orally available multiple sclerosis drug Tecfidera have been crushing already lofty sales expectations. The drug brought in $876 million in its first year on the market, even while Biogen's other MS offerings Tysabri and Avonex continued to grow. Couple that with growth in other orally available drugs from Novartis and Sanofi, and Copaxone, even with an improved dosing schedule, could continue to lose market share.

The bottom line
New management could certainly bring life to the struggling company. If the new formulation of Copaxone can grasp market share before Mylan unrolls its biosimilar, then Teva should be able to stave off the competition. If not, the combination of generic and next-generation competition could wipe out revenue and earnings for some time.

Cost-cutting can soften the blow, but it can't carry the bottom line forever. The real goal for Teva should be to improve its generics pipeline, as growth of that sector has also stalled.

Seth Robey has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$11.19 (-0.18%) $0.02
Biogen Inc. Stock Quote
Biogen Inc.
$222.17 (0.53%) $1.18
Viatris Inc. Stock Quote
Viatris Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.